Feasibility of monitoring advanced melanoma patients using cell‐free DNA from plasma
Gangadhar T, Savitch S, Yee S, Xu W, Huang A, Harmon S, Lieberman D, Soucier D, Fan R, Black T, Morrissette J, Salathia N, Waters J, Zhang S, Toung J, van Hummelen P, Fan J, Xu X, Amaravadi R, Schuchter L, Karakousis G, Hwang W, Carpenter E. Feasibility of monitoring advanced melanoma patients using cell‐free DNA from plasma. Pigment Cell & Melanoma Research 2017, 31: 73-81. PMID: 28786531, PMCID: PMC5742050, DOI: 10.1111/pcmr.12623.Peer-Reviewed Original ResearchConceptsCell-free DNAStage III/IV patientsTissue next-generation sequencingAdvanced melanoma patientsMonitoring of patientsPrevious therapyIV patientsAdvanced melanomaMelanoma patientsTumor burdenBlood drawUltra-deep sequencingPatientsPlasma mutationsLiquid biopsyNext-generation sequencingFrequent mutationsAllele fractionTherapyMore mutationsMutationsBiopsyMelanomaBRAF